resTORbio to Host its 2020 Annual Shareholder Meeting Virtually on June 3, 2020
Shareholders at the close of business on the record date,
Shareholders of record may vote by internet at www.proxyvote.com, by telephone using a touch-tone telephone at 1-800-690-6903 or by marking, signing and dating the proxy card and returning it in the postage-paid envelope provided to Vote Processing, c/o Broadridge,
Please note that the proxy card and voting instruction form included with previously distributed proxy materials will not be updated to reflect the change from an in-person meeting to a virtual-only meeting and may be used to vote shares in connection with the annual meeting. Whether or not shareholders plan to attend the virtual-only annual meeting, resTORbio urges shareholders to vote and submit their proxies in advance of the meeting by one of the methods described in the proxy materials.
resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to treat aging-related diseases. resTORbio’s lead program selectively inhibits TORC1, an evolutionarily conserved pathway that contributes to the decline in function of aging organ systems, including neurologic function. Learn more about resTORbio, Inc. at www.resTORbio.com.
Stern Investor Relations, Inc.